California 2024 - Prostate Cancer Facts & Statistics

Download CALIFORNIA'S 2024 Prostate Cancer Facts & Statistics Sheet

Incidence Rates

• Given 100,000 California men, 95.4 will be diagnosed with prostate cancer in their lifetime.
• 26,350 will be diagnosed this year.
• The state is ranked #48 in the country for prostate cancer incidences.

Mortality Rates

• 19.8 in every 100,000 men will die from prostate cancer in California.
• 4,200 men in the state, this year alone.
• The state is ranked #21 in the country for prostate cancer deaths.

CDMRP Grants in California

Year Introduced: 1997

Total Grants to Date: 553

Total Grand Awards Through FY 2022**: $283.27M

Grant Recipient	Year	Amount
University Of California San Francisco	2012	$9,455,882
University Of Southern California	1999	$2,200,891
University Of California Los Angeles	1999	$1,764,226
Sanford Burnham Prebys Medical Discovery Institute, La Jolla	2022	$1,755,000
University Of California San Diego	2013	$1,681,618

* Congressionally Directed Medical Research Programs 
**PCRP (Prostate Cancer Research Program) data for FY 2023 has not yet been posted

CDC’s National Comprehensive Cancer Control Program (NCCCP) Funding in California

• For prostate cancer, recommendations encouraging informed decision-making regarding screening are emphasized rather than focusing on increasing screening rates.
• Objective: By 2015, increase the proportion of men 40 years and older who have talked with their healthcare providers about prostate cancer screening.
• Strategy: Educate men about prostate cancer, its risk factors, and screening benefits and risks, and encourage them to consult with their healthcare providers and participate in shared decision-making regarding prostate cancer screening.
• Strategy: Educate primary care providers to utilize appropriate risk assessment tools and discuss with their male patients the risks and benefits of prostate cancer screening to promote informed decision making at appropriate ages depending upon patients’ risk factors.
• Strategy: Develop questions for prostate cancer screening regarding family history and informed decision making to include in data surveillance tools.
• Strategy: Continue to monitor medical science and screening recommendations and unify the messages from cancer authorities about the benefits and risks of prostate cancer screening to promote informed decision making.
• Strategy: Support funding for research to identify better screening tools for prostate cancer and to develop new and effective treatment options.
• Objective: African American men have the highest incidence and mortality rates for prostate cancer in California among all men. In addition, across all ethnic groups in California, African American men are among those with the lowest screening rates. By 2015, increase the percentage of African Americans (non-Hispanic black) men 40 years and older who have ever had Prostate Specific Antigen (PSA) screening by 20 percent, from the current baseline of 61.2% to 73.4%.  
• Strategy: Continue to monitor medical science and screening recommendations, and unify the message from cancer authorities about the benefits and risks of prostate cancer screening to promote informed decision making. Educate primary care providers to utilize appropriate risk assessment tools and provide comprehensive, consistent, and balanced information about prostate screening to promote informed decision making for African American men 40 years and older. 
• Strategy: Educate African American men 40 years and older who are at high risk for prostate cancer about prostate cancer risk factors, screening benefits and options, and the importance of consulting their healthcare providers and participating in shared decision making regarding prostate cancer screening. 
• Objective: By 2015, decrease the mortality rate of prostate cancer among all Californians by ten percent, from the current baseline rate of 21.7/100,000 to 19.5/100,000. 
• Objective: By 2015, decrease the mortality rate of prostate cancer among African American (non-Hispanic black) men by ten percent, from the current baseline rate of 51.6/100,000 to the target rate of 46.4/100,000. 
• Strategy: Increase access to screening and treatment for men, especially those at increased risk. Support continued and/or increased funding for the state prostate cancer treatment program for uninsured and under-insured men. Compile and post a list of free or low-cost prostate cancer treatment resources. 
• Strategy: Support funding for research to identify better screening tools for prostate cancer and to develop new, effective treatment options

Legislative Action

In the 2021 legislative session, ZERO was proud to support AB 1520, a bill to eliminate cost-sharing for prostate cancer screening for high-risk men.